The Brisbane-based corporate team at McCullough Robertson is led by Reece Walker, a specialist in the life sciences, technology and telecoms sectors. The team also supports clients across the construction and engineering, transport and logistics, and resources and renewables industries, with a specific focus on assisting founders seeking capital raising advice at both the start-up and expansion capital phases. Ben Wood has particular expertise regarding financial services clients, while special counsel Naomi Omundson advises clients across Australia and the US with a notable emphasis on the life sciences sector.
Testimonials
Collated independently by Legal 500 research team.
‘All dealings with McCullough Robertson equity capital markets practice have been commercially pragmatic, high quality and cost effective. The team generally communicates well and seeks practical solutions to challenges.'
‘Reece Walker is a great leader and highly experienced lawyer with a common-sense and practical approach to issues. Highly responsive and thinks holistically.'
- 'Ben Wood communicates and explains things well and is very competent. Very client focused and practical in the application of legal issues.'
- 'Naomi Omundson is another outstanding member of the team with a practical approach, attention to detail, and excellent skills in communication and the application of the law.’
Key clients
- LGI Limited
- SOCO Corporation Limited
- Imugene Limited
- Prescient Therapeutics Limited
- Chimeric Therapeutics Limited
- Radiopharm Theranostics Limited
- Implicit Bioscience Limited
- Bell Potter Securities Limited and Canaccord Genuity (Australia) Limited
- Diatreme Resources Limited
- Group 6 Metals Limited
- KGL Resources Limited
- ECP Emerging Growth Limited
Work highlights
- Advised LGI Limited in relation to its successful $25 million IPO, which resulted in a market cap of $130 million.
- Assisted Imugene Limited in raising funds to provide an extended runway for Imugene’s deep pipeline of clinical programmes.
- Assisted Prescient Therapeutics in raising funds to be used by PTX to progress its deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200 and progressing its innovative cell therapies towards first-in-human clinical studies.
Practice head
The lawyer(s) leading their teams.
Reece Walker